Filtered By:
Specialty: Cardiology
Drug: Insulin

This page shows you your search results in order of relevance. This is page number 4.

Order by Relevance | Date

Total 191 results found since Jan 2013.

The association of the treatment with glucagon-like peptide-1 receptor agonist exenatide or insulin with cardiovascular outcomes in patients with type 2 diabetes: a retrospective observational study
Background: To evaluate the association of treatment with glucagon-like peptide-1 (GLP-1) receptor agonist exenatide and/or insulin on macrovascular outcomes in patients with type 2 diabetes (T2DM). Methods: We conducted a retrospective longitudinal pharmaco-epidemiological study using large ambulatory care data to evaluate the risks of heart failure (HF), myocardial infarction (MI) and stroke in established T2DM patients who received a first prescription of exenatide twice daily (EBID) or insulin between June 2005 and May 2009, with follow-up data available until December 2012. Three treatment groups were: EBID with oral ...
Source: Cardiovascular Diabetology - January 24, 2015 Category: Cardiology Authors: Sanjoy PaulKerenaftali KleinDavid MaggsJennie Best Source Type: research

Abstract 013: Using the Diabetes Collaborative Registry (DCR) to Estimate the Potential Real-world Impact of the Iris Trial on Improving Outcomes in Patients With Cerebrovascular Disease Session Title: Poster Session I
Conclusion: In a large US-based outpatient registry, we found that 12% of outpatients with prediabetes or diet-controlled T2D met the main eligibility criteria for IRIS, partly due to the narrow inclusion criteria of the trial but also likely reflective of a general paucity of screening for prediabetes and insulin resistance in this cohort. Pioglitazone was rarely used in these patients but could have a substantial impact on CV outcomes in these eligible patients. The population impact could be even greater if the CV benefit of pioglitazone can be demonstrated in patients with cerebrovascular disease and overt T2D or even ...
Source: Circulation: Cardiovascular Quality and Outcomes - March 31, 2017 Category: Cardiology Authors: Arnold, S. V., Inzucchi, S. E., Tang, F., McGuire, D. K., Mehta, S. N., Maddox, T. M., Goyal, A., Sperling, L. S., Einhorn, D., Wong, N. D., Kosiborod, M. Tags: Session Title: Poster Session I Source Type: research

Pioglitazone and cardiovascular risk reduction: time for a second look?
Insulin resistance, a fundamental pathophysiological abnormality in patients with type 2 diabetes, is associated with increased cardiovascular (CV) disease risk. In diabetes management, the macrovascular impact of antihyperglycemic agents that do not improve insulin sensitivity has generally been disappointing. In contrast, glucose-lowering drugs that work as insulin sensitizing agents have been postulated to reduce CV complications. The data to support this hypothesis have, however, been inconsistent. The impact of thiazolidinediones on macrovascular events is of particular interest. In this review, we discuss the results...
Source: Cardiovascular Endocrinology - May 12, 2017 Category: Cardiology Tags: Review articles Source Type: research

Differentiating Associations of Glycemic Traits with Atherosclerotic and Thrombotic Outcomes: Mendelian Randomization Investigation
Diabetes. 2022 May 2:db210905. doi: 10.2337/db21-0905. Online ahead of print.ABSTRACTWe conducted a Mendelian randomization analysis to differentiate associations of four glycemic indicators with a broad range of atherosclerotic and thrombotic diseases. Independent genetic variants associated with fasting glucose (FG), 2-h glucose after an oral glucose challenge (2hGlu), fasting insulin (FI), and glycated hemoglobin (HbA1c) at the genome-wide significance threshold were used as instrumental variables. Summary-level data for 12 atherosclerotic and 4 thrombotic outcomes were obtained from large genetic consortia and the Finn...
Source: Atherosclerosis - May 2, 2022 Category: Cardiology Authors: Shuai Yuan Amy M Mason Stephen Burgess Susanna C Larsson Source Type: research

The relationship between glycaemic variability and cardiovascular complications in patients with acute myocardial infarction and type 2 diabetes: a report from the DIGAMI 2 trial
Conclusion The 1-year risk for death, reinfarction, or stroke did not relate to glycaemic variability in T2DM patients with AMI treated with insulin infusion.
Source: European Heart Journal - February 1, 2013 Category: Cardiology Authors: Mellbin, L. G., Malmberg, K., Ryden, L., Wedel, H., Vestberg, D., Lind, M. Tags: Coronary artery disease Source Type: research

Mediterranean diet and physical activity: An intervention study. Does olive oil exercise the body through the mind?
Several studies address how different features of unhealthy lifestyle and obesity are detrimental in cardiovascular disease . The Mediterranean diet, assumed as a paradigm of healthy nutrition, is still studied, envisaging even pharmacological effects . Other scientific contributions, without correct information, could be more negative than useful for the enhancement of healthier behavior: actually, in such studies, the successful counseling focused to secondary prevention-treatment should deserve more emphasis and dissemination. A recent investigation claims that an energy-unrestricted Mediterranean diet supplemented with...
Source: International Journal of Cardiology - May 28, 2013 Category: Cardiology Authors: Daniela Catalano, Guglielmo M. Trovato, Patrizia Pace, Giuseppe Fabio Martines, Francesca M. Trovato Tags: Letters to the Editor Source Type: research

Design of the liraglutide effect and action in diabetes: Evaluation of cardiovascular outcome results (LEADER) trial
Conclusions: LEADER commenced in September 2010, and enrollment concluded in April 2012. There were 9,340 patients enrolled at 410 sites in 32 countries. The mean age of patients was 64.3 ± 7.2 years, 64.3% were men, and mean body mass index was 32.5 ± 6.3 kg/m2. There were 7,592 (81.3%) patients with prior CVD and 1,748 (18.7%) who were high risk but without prior CVD. It is expected that LEADER will provide conclusive data regarding the cardiovascular safety of liraglutide relative to the current standard of usual care for a global population of patients with T2DM.
Source: American Heart Journal - October 4, 2013 Category: Cardiology Authors: Steven P. Marso, Neil R. Poulter, Steven E. Nissen, Michael A. Nauck, Bernard Zinman, Gilbert H. Daniels, Stuart Pocock, William M. Steinberg, Richard M. Bergenstal, Johannes F.E. Mann, Lasse Steen Ravn, Kirstine Brown Frandsen, Alan C. Moses, John B. Bus Tags: Trial Design Source Type: research

Rationale and design of the Steroids in Cardiac Surgery trial
Conclusions: SIRS will lead to a better understanding of the safety and efficacy of prophylactic steroids for cardiac surgery requiring CBP.
Source: American Heart Journal - March 3, 2014 Category: Cardiology Authors: Richard Whitlock, Kevin Teoh, Jessica Vincent, P.J. Devereaux, Andre Lamy, Domenico Paparella, Yunxia Zuo, Daniel I. Sessler, Pallav Shah, Juan-Carlos Villar, Ganesan Karthikeyan, Gerard Urrútia, Alvaro Alvezum, Xiaohe Zhang, Seyed Hesameddin Abbasi, Hon Tags: Trial Design Source Type: research

Evaluating Cardiovascular Safety of Novel Therapeutic Agents for the Treatment of Type 2 Diabetes Mellitus
Abstract Type 2 diabetes increases the risk of developing cardiovascular (CV) complications such as myocardial infarction, heart failure, stroke, peripheral vascular disease, and CV-associated mortality. Strict glycemic control in diabetics has shown improvement in microvascular complications related to diabetes but has been unable to demonstrate major effects on macrovascular complications including myocardial infarction and stroke. Conventional therapies for diabetes that include insulin, metformin, sulfonylureas (SU), and alpha-glucosidase inhibitors have limited and/or controversial data on CV safety based on...
Source: Current Cardiology Reports - October 10, 2014 Category: Cardiology Source Type: research

Design of the liraglutide effect and action in diabetes: Evaluation of cardiovascular outcome results (LEADER) trial
Conclusions LEADER commenced in September 2010, and enrollment concluded in April 2012. There were 9,340 patients enrolled at 410 sites in 32 countries. The mean age of patients was 64.3 ± 7.2 years, 64.3% were men, and mean body mass index was 32.5 ± 6.3 kg/m2. There were 7,592 (81.3%) patients with prior CVD and 1,748 (18.7%) who were high risk but without prior CVD. It is expected that LEADER will provide conclusive data regarding the cardiovascular safety of liraglutide relative to the current standard of usual care for a global population of patients with T2DM.
Source: American Heart Journal - October 20, 2014 Category: Cardiology Source Type: research

Hypertension in diabetes: optimal pharmacotherapy.
Authors: Biswas A, Alvarez A, Mukherjee D Abstract Hypertension is commonly associated with diabetes mellitus. The combination of hypertension with obesity and diabetes is a well recognized entity known as the metabolic syndrome, which shares a common pathophysiology of insulin resistance. The individual components of this syndrome act synergistically to substantially increase the risk of renal disease, stroke, coronary artery disease, and death. Hypertension increases both macrovascular and microvascular complications of diabetes such as neuropathy, nephropathy, coronary artery disease, stroke, and retinopathy. He...
Source: Cardiovascular and Hematological Agents in Medicinal Chemistry - November 23, 2014 Category: Cardiology Tags: Cardiovasc Hematol Agents Med Chem Source Type: research

G-Protein β 3 -Subunit Gene C825T Polymorphism and Cardiovascular Risk: An Updated Review
Abstract Hypertension is a common disorder of multifactorial origin that constitutes a major risk factor for cardiovascular events such as stroke and myocardial infarction. The subunits of the heterotrimeric G proteins are attractive candidate gene products for susceptibility to hypertension, obesity and insulin resistance syndrome. A polymorphism (825C/T) in exon 10 of the GNB3 gene, encoding for the Gβ3 subunit, has been described. The 825T allele is associated with alternative splicing of the gene and formation of a truncated but functionally active β3 subunit. Many studies have investigated whether carriers ...
Source: High Blood Pressure and Cardiovascular Prevention - April 23, 2015 Category: Cardiology Source Type: research

Serial Measurement of High Sensitivity Troponin I and Cardiovascular Outcomes in Patients with Type 2 Diabetes Mellitus in the EXAMINE Trial.
Conclusions -Serial assessment of hsTnI revealed a substantial proportion of patients with T2DM without clinically recognized events had dynamic or persistently elevated values and were at high risk of recurrent events. hsTnI may have a role in personalizing preventive strategies in patients with diabetes based on risk. Clinical Trial Registration -https://clinicaltrials.gov Identifier: NCT00968708. PMID: 28246236 [PubMed - as supplied by publisher]
Source: Circulation - February 27, 2017 Category: Cardiology Authors: Cavender MA, White WB, Jarolim P, Bakris GL, Cushman WC, Kupfer S, Gao Q, Mehta CR, Zannad F, Cannon CP, Morrow DA Tags: Circulation Source Type: research

Circulating Branched-Chain Amino Acids and Incident Cardiovascular Disease in a Prospective Cohort of US Women Original Articles
Conclusions: Circulating plasma BCAAs were positively associated with incident CVD in women. Impaired BCAA metabolism may capture the long-term risk of the common cause underlying T2D and CVD.
Source: Circulation: Cardiovascular Genetics - March 23, 2018 Category: Cardiology Authors: Tobias, D. K., Lawler, P. R., Harada, P. H., Demler, O. V., Ridker, P. M., Manson, J. E., Cheng, S., Mora, S. Tags: Biomarkers, Cardiovascular Disease, Diabetes, Type 2, Epidemiology, Women Original Articles Source Type: research